Occult pneumococcal bacteremia: A review

Pediatric Emergency Care

Volumn 26, Issue 6, 2010, Pages 448-457

  Joffe, Mark D ^a,b   Alpern, Elizabeth R ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bacteremia; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT;

BACTEREMIA; BLOOD CULTURE; BODY TEMPERATURE; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG DOSE COMPARISON; EMERGENCY CARE; FEVER; FOLLOW UP; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MENINGITIS; MICROBIOLOGY; OCCULT BACTEREMIA; PATHOPHYSIOLOGY; PEDIATRICS; PREVALENCE; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; STREPTOCOCCUS PNEUMONIAE; ANTIBIOTIC RESISTANCE; DECISION SUPPORT SYSTEM; DIFFERENTIAL DIAGNOSIS; INFANT; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD, PRESCHOOL; DECISION SUPPORT TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK FACTORS;

EID: 77953341837     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e3181e15e36     Document Type: Review

References (68)

1. Torphy DE, Ray CG. Occult pneumococcal bacteremia. Am J Dis Child. 1970;119:336-338.
2. Belsey MA. Pneumococcal bacteremia: a report of three cases. Am J Dis Child. 1967;113:588-589.
3. McGowan J, Bratton L, Klein J, et al. Bacteremia in febrile children seen in a Bwalk-in[ pediatric clinic. N Engl J Med. 1973;288:1309-1312.
4. Michaels RH. Increase in H. influenzae meningitis. NEJM. 1971;285:666-667.
5. Feigen RD. Bacterial meningitis beyond the neonatal period. In: Feigen JD, Cherry JD, eds. Textbook of Pediatric Infections Diseases. Philadelphia, PA: Saunders; 1981:293.
6. Parke JC, Jr, Schneerson R, Robbins JB. The attack rate, age, incidence, racial distribution and case fatality rate of Haemophilus influenza B meningitis in Mecklenburg County, North Carolina. J Pediatr. 1972;81:765-769.
7. Marshall R, Teele DW, Klein JO. Unsuspected bacteremia due to Haemophilus influenzae: outcome in children not initially admitted to hospital. J Pediatr. 1979;95:690-695.
8. Progress toward elimination of Haemophilus influenzae type B disease among infants and childrenVUnited States, 1987-1995. MMWR. 1996;45(42):901-906.
9. Huang SS, Platt R, Rifas-Shiman SL, et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics. 2005;116(3):e408Ye413.
10. Millar EV, O'Brien KL, Watt JP, et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis. 2006;43(1):8-15.
11. Cardozo DM, Nascimento-Carvalho CM, Andrade AL, et al. Prevalence and risk factors for nasopharyngeal carriage of Streptococcus pneumoniae among adolescents. J Med Microbiol. 2008;57(Pt 2):185-189.
12. Briles DE, Novak L, Hotomi M, et al. Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun. 2005;73(10):6945-6951.
13. Brueggemann AB, Griffiths DT, Meats E et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and close-specific differences in invasive disease potential. J Infect Dis. 2003;187:1424-1432.
14. Alpern ER, Alessandrini EA, Bell LM, et al. Serotype prevalence of occult pneumococcal bacteremia. Pediatrics. 2001;108(8):e23. Available at: http://www.pediatrics.org/cgi/content/full/108/8/e23. Accessed August 20, 2009.
15. Bratton L, Teele DW, Klein JO. Outcome of unsuspected pneumococcal bacteremia in children not initially admitted to the hospital. J Pediatr. 1977;90:703-706.
16. Alpern ER, Alessandrini EA, Bell LM, et al. Occult bacteremia from a pediatric emergency department: current prevalence, time to detection, and outcome. Pediatr. 2000;106:505-511.
17. Klein JO. Bacterial pneumonias. In: Feigen JD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. Philadelphia, PA: Saunders; 1987:333.
18. Kuppermann N, Fleisher GR, Jaffe DM. Predictors of occult pneumococcal bacteremia in young febrile children. Ann Emerg Med. 1998;31(6):679-687.
19. Fleisher GR, Rosenberg N, Vinci R, et al. Intramuscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia. J Pediatr. 1994;124(4):504-512.
20. McCarthy PL, Lembo RM, Baron MA, et al. Predictive value of abnormal physical examination findings in ill-appearing and well-appearing febrile children. Pediatrics. 1985;76(2):167-171.
21. Kahn HA, Sempos CT. Statistical Methods in Epidemiology. New York, New York: Oxford University Press; 1989.
22. Jaffe D, Tanz R, Davis T, et al. Antibiotic administration to treat possible occult bacteremia in febrile children. N Engl J Med. 1987;317:1175-1180.
23. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med. 2004;158:671-675.
24. Lee GM, Harper MB. Risk of bacteremia for febrile young children in the postYHaemophilus influenzae type B era. Arch Pediatr Adolesc Med. 1998;152(5):624-628.
25. Young PC. The management of febrile infants by primary-care pediatricians in Utah: comparison with published practice guidelines. Pediatrics. 1995;95(5):623-628.
26. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
27. Vakevainen M, Eklund C, Eskola J, et al. Cross reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae evoked by pneumococcal conjugate vaccines in infants. J Infect Dis. 2001;184(6):789-793.
28. Herz AM, Greenhow TL, Alcantara J, et al. Changing epidemiology of outpatient bacteremia in 3 to 36 month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2006;25:293-300.
29. Carstairs K, Tasnen D, Johnson AS, et al. Pneumococcal bacteremia in febrile infants presenting to the emergency department before and after the introduction of the heptavalent pneumococcal vaccine. Ann Emerg Med. 2007;49:772-777.
30. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-449.
31. Kyaw MH, Lynfield R, Schaffner W, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-1463.
32. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746.
33. Peters TR, Poehling KA. Invasive pneumococcal disease. JAMA. 2007;297(16):1825-1826.
34. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-1792.
35. Schutzman S, Petrycki S, Fleisher G. Bacteremia with otitis media. Pediatrics. 1991;87(1):48-53.
36. Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185:1124-1131.
37. Jaffe DM, Fleisher GR. Temperature and total white blood cell count as indicators of bacteremia. Pediatrics. 1991;87(5):670-674.
38. Isaacman DJ, Shults J, Gross TK, et al. Predictors of bacteremia in febrile children 3 to 36 months of age. Pediatrics. 2000;106(5):977-982.
39. Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0-36 months of age with fever without source. Pediatrics. 1993;92:1-12.
40. Bass J, Steele R, Wittler R, et al. Antimicrobial treatment of occult bacteremia: a multicenter cooperative study. Pediatr Infect Dis J. 1993;12:466-473.
41. Pulliam PN, Attia MW, Cronan KM. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics. 2001;108(6):1275-1279.
42. Isaacman DJ, Burke BL. Utility of the serum C-reactive protein for detection of occult bacterial infection in children. Arch Pediatr Adolesc Med. 2002:156(9):905-909.
43. Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics. 2003;112: 1054-1060.
44. Rubin LG, Carmody L. Pneumococcal and Haemophilus influenzae type B antigen detection in children at risk for occult bacteremia. Pediatrics. 1987;80(1):92-96.
45. Neuman MI, Harper MB. Rapid antigen assay for the diagnosis of pneumococcal bacteremia in children: a preliminary study. Ann Emerg Med. 2002;40(4):399-404.
46. Ramilo O, Allman W, Chung W, et al. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood. 2007;109(5):2066-2077.
47. Joffe MD, Avner JR. Follow-up of patients with occult bacteremia in pediatric emergency departments. Pediatr Emerg Care. 1992;8(5):258-261.
48. Alario AJ, Nelson EW, Shapiro ED. Blood cultures in the management of febrile outpatients later found to have bacteremia. J Pediatr. 1989;115:195-199.
49. Neuman MI, Harper MB. Time to positivity of blood cultures with Streptococcus pneumoniae bacteremia. Clin Infect Dis. 2001;33:1324-1328.
50. Bachur R, Harper MB. Reevaluation of outpatients with Streptococcus pneumoniae bacteremia. Pediatrics. 2000;105(3):502-509.
51. Waltzman ML, Harper M. Financial and clinical impact of false-positive blood culture results. Clin Infect Dis. 2001;33:296-299.
52. Teele DW, Pelton SI, Grant MJ, et al. Bacteremia in febrile children under 2 years of age: results of cultures of blood of 600 consecutive febrile children seen in a Bwalk-in[ clinic. J Pediatr. 1975;87(2):227-230.
53. Carroll WL, Farrell MKI, Singer JI, et al. Treatment of occult bacteremia: a prospective randomized clinical trial. Pediatrics. 1983;72(5):608-612.
54. Baraff LJ, Bass JW, Fleisher GR, et al. Commentary on practice guidelines. Pediatrics. 1997;100(1):134-135.
55. Kramer MS, Shapiro ED. Management of the young febrile child: a commentary on recent practice guidelines. Pediatrics. 1997;100(1):128-133.
56. Bulloch B, Craig WR, Klassen TP. The use of antibiotics to prevent serious sequelae in children at risk for occult bacteremia: a meta-analysis. Acad Emerg Med. 1997;4:679-683.
57. Rothrock SG, Harper MB, Green SM, et al. Do oral antibiotics prevent meningitis and serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia? A meta-analysis. Pediatrics. 1997;99(3):438-444.
58. Rothrock SG, Green SM, Harper MB, et al. Parenteral vs oral antibiotics in the prevention of serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia: a meta-analysis. Acad Emerg Med. 1998;5(6):599-606.
59. Kramer MS, Lane DA, Mills E. Should blood cultures be obtained in the evaluation of young febrile children without evident focus of bacterial infection? A decision analysis of diagnostic management strategies. Pediatrics. 1989;84(1):18-27.
60. Downs SM, McNutt RA, Margolis PA. Management of infants at risk for occult bacteremia: a decision analysis. J Pediatr. 1991;118:11-20.
61. Lieu TA, Schwartz S, Jaffe DM, et al. Strategies for diagnosis and treatment of children at risk for occult bacteremia: clinical effectiveness and cost-effectiveness. J Pediatr. 1991;118:21-29.
62. Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics. 2001;108(4):835-844.
63. Madsen KA, Bennett JE, Downs SM. The role of parental preferences in the management of fever without source among 3- to 36-month-old children: a decision analysis. Pediatrics. 2006;117(4):1067-1076.
64. Bennett JE, Sumner W II, Downs SM, et al. Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154:43-48.
65. Caviness AC, Cantor SB, Coburn HA, et al. A cost-effectiveness analysis of bacterial endocarditis prophylaxis for febrile children who have cardiac lesions and undergo urinary catheterization in the emergency department. Pediatrics. 2004;113(5):1291-1296
66. Bayley MD, Schwarts JS, Shofer FS, et al. The financial burden of emergency department congestion and hospital crowding for chest pain patients awaiting admission. Ann Emerg Med. 2005;45(2):110-117.
67. Kuppermann N. The evaluation of young febrile children for occult bacteremia: time to reevaluate our approach? Arch Pediatr Adolesc Med. 2002;156:855-856.
68. Pines JM, Szyld D. Risk tolerance for the exclusion of potentially life-threatening diseases in the ED. Am J Emerg Med. 2007;25(5):540-544.